The Patient-Centric Synergy of Pharmaceutical CDMO and CRO Collaborations
Pharmaceutical collaborations are nothing new to the industry. Increasingly complex drug development programs, calls for supply chain resiliency, and the involvement of all key stakeholders throughout a drug’s development lifecycle are pushing contract development and manufacturing organisations to partner with their counterparts in research.
Deals between pharmaceutical CDMOs and CROs have resulted in billions of dollars in M&A transactions. 48 deals between pharmaceutical CDMOs and CROs were made in the first half of 2021 alone. The CMO industry counted 479 deals between 2018–2022 of either whole companies or individual facilities.
The benefits of these partnerships and M&A decisions include:
-
Efficient speed-to-market processes
The drug discovery, development, and commercial pipeline will benefit from fewer disruptions and transfers of samples, products, and technologies between companies. Ultimately, a pharmaceutical CDMO and CRO collaboration aims to provide ample product availability on shorter timescales.
-
Clinical trial support
The organisation and orchestration of a clinical trial will benefit from clear and concise communication between pharmaceutical CDMOs and CROs in partnership. Expanded geographic reaches offered by both organisations can increase access to expertise in specialised therapeutic areas and establish patient-centred trial frameworks. Decentralised clinical trials are also on the rise as patients become more invested in their healthcare treatment journeys.
-
An industry-wide mindset shift
"Companies and their leadership have to be very intentional about the values that they are embedding into the organisation,” states Brenda Bruker, Thermo Fisher Scientific’s Executive Director, Integrated Supply and Delivery Services. “A shared vision and values from the top and across all teams is critical. That’s part of what we do – we drive that level of communication and training across the organisation to ensure that everybody understands their role in the process, even down to each individual and what role they can play in maximising the customer experience.”
This idea of optimising a patient’s experience with the drug they are taking is not a new idea. Patient-centricity has been a main topic of discussion throughout the pharmaceutical supply chain. Pharmaceutical players who want to position themselves as leaders in the industry must begin to consider the patient as integral to the design and manufacture of their product. As the industry blurs the operational designations between CDMOs and CROs, an intentional collaboration between the two can result in the patient-centric future the industry has been discussing for years.
Our latest Trend Report in collaboration with Thermo Fisher Scientific Inc. takes a look at how collaborations between CDMOs and CROs have developed and where they intend to go. We also examine how such partnerships can ultimately lead the drive towards patient-centricity within the pharmaceutical industry, paving the way for a true nexus between patient and Big Pharma.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance